Hyponatremia, or low serum sodium levels, is a common electrolyte imbalance that can have serious complications if left untreated. It is estimated that between 10-20% of hospitalized patients have hyponatremia. It is especially common among elderly patients, who are more likely to suffer from multiple comorbidities that can contribute to the condition. Euvolemic hyponatremia, which is characterized by normal total body water and sodium levels, is the most common type of hyponatremia seen in clinical practice. In this article, we will discuss the pathophysiology of euvolemic hyponatremia, as well as the current treatment strategies and emerging therapies. We will also discuss the importance of early diagnosis and management in order to reduce the risk of serious complications.
Euvolemic hyponatremia is caused by an imbalance between the rate of water intake and the rate of water excretion. It is most commonly caused by a defect in the body's ability to excrete water, such as in the case of Syndrome of Inappropriate Antidiuretic Hormone (SIADH). In SIADH, the body is unable to excrete excess water, leading to an accumulation of water in the body and a decrease in serum sodium levels. Other causes of euvolemic hyponatremia include psychogenic polydipsia, diuretic therapy, and certain medications. In addition, certain medical conditions, such as liver cirrhosis, congestive heart failure, and renal failure, can lead to euvolemic hyponatremia.
The primary goal of treatment for euvolemic hyponatremia is to restore the serum sodium level to a safe range. This can be accomplished through a combination of lifestyle modifications, medications, and intravenous fluids. Lifestyle modifications such as reducing fluid intake, avoiding alcohol, and increasing salt intake can help to reduce the severity of symptoms. Medications such as diuretics, vasopressin receptor antagonists, and loop diuretics can help to reduce the amount of water in the body and restore normal serum sodium levels. Intravenous fluids can also be used to replace lost electrolytes and restore normal sodium levels.
In recent years, researchers have been exploring new therapeutic strategies for the treatment of euvolemic hyponatremia. One such strategy is the use of the vasopressin antagonist tolvaptan. Tolvaptan is a selective, non-peptide V2 receptor antagonist that has been shown to be effective in increasing serum sodium levels in patients with euvolemic hyponatremia. In addition, researchers are exploring the use of hypertonic saline to treat euvolemic hyponatremia. Hypertonic saline can rapidly increase serum sodium levels and has been shown to be safe and effective in clinical trials.
Euvolemic hyponatremia is a common electrolyte imbalance that can have serious complications if left untreated. The primary goal of treatment is to restore the serum sodium level to a safe range. Current treatment strategies include lifestyle modifications, medications, and intravenous fluids. In addition, researchers are exploring new therapeutic strategies, such as the use of vasopressin antagonists and hypertonic saline. Early diagnosis and management of euvolemic hyponatremia is essential in order to reduce the risk of serious complications.
1.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Hereditary cancer has a rare and underreported cause.
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
1.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Essential Updates in Hematology in Daily Practice
4.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
5.
Importance of Early Detection in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation